Pancreatic Cancer Research

ResearcherShimane UniversityActive in the last 2 years

Yasunari Kawabata

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3350-530X; OpenAlex author ID A5051078028. Sources: OpenAlex.

Their work

Papers
7
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 7

  1. Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter… Co-author DOI 10.1002/ags3.70001↗
  2. Laparoscopic versus open radical antegrade modular pancreatosplenectomy with artery-first approach in pancreatic cancer. Co-author DOI 10.1007/s00423-020-01887-y↗
  3. Antidiabetic adiponectin receptor agonist AdipoRon suppresses tumour growth of pancreatic cancer by inducing RIPK1/ERK-dependent necroptosis. Co-author DOI 10.1038/s41419-018-0851-z↗
  4. MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomize… Co-author DOI 10.1186/s13063-018-3002-z↗
  5. Modified total meso-pancreatoduodenum excision with pancreaticoduodenectomy as a mesopancreatic plane surgery in borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.ejso.2016.02.241↗
  6. Superior mesenteric artery-first approach in radical antegrade modular pancreatosplenectomy for borderline resectable pancreatic cancer: a technique to obtain … Co-author DOI 10.1016/j.jamcollsurg.2014.12.054↗
  7. Low expression of nucleus accumbens-associated protein 1 predicts poor prognosis for patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/pin.12020↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshitsugu Tajima · 5 shared papers, 2012–2020 · strength 0.41
  2. Sohei Satoi · 2 shared papers, 2018–2025 · strength 0.23
  3. Yuko Mataki · 2 shared papers, 2018–2025 · strength 0.23
  4. Ippei Matsumoto · 2 shared papers, 2018–2025 · strength 0.23
  5. Tsutomu Fujii · 2 shared papers, 2018–2025 · strength 0.23
  6. Yosuke Inoue · 1 shared paper, 2025 · strength 0.17
  7. So Yamaki · 1 shared paper, 2025 · strength 0.17
  8. Yuki Homma · 1 shared paper, 2025 · strength 0.17
  9. Tetsuya Ikemoto · 1 shared paper, 2025 · strength 0.17
  10. Katsuhisa Hirano · 1 shared paper, 2025 · strength 0.17
  11. Joji Kitayama · 1 shared paper, 2025 · strength 0.17
  12. Masamichi Mizuma · 1 shared paper, 2025 · strength 0.17
  13. Toshimichi Asano · 1 shared paper, 2025 · strength 0.17
  14. Atsushi Oba · 1 shared paper, 2025 · strength 0.17
  15. Yasutoshi Kimura · 1 shared paper, 2025 · strength 0.17
  16. Daisuke Hashimoto · 1 shared paper, 2025 · strength 0.17
  17. Tomohisa Yamamoto · 1 shared paper, 2025 · strength 0.17
  18. Hiromitsu Maehira · 1 shared paper, 2025 · strength 0.17
  19. Makoto Yoshida · 1 shared paper, 2025 · strength 0.17
  20. Yasuhiro Kodera · 1 shared paper, 2025 · strength 0.17
  21. Michiaki Unno · 1 shared paper, 2025 · strength 0.17
  22. Fuyuhiko Motoi · 1 shared paper, 2025 · strength 0.17
  23. Masafumi Nakamura · 1 shared paper, 2025 · strength 0.17
  24. Takeshi Nishi · 2 shared papers, 2012–2020 · strength 0.16
  25. Keizo Takenaga · 2 shared papers, 2012–2018 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.